ECSP22003599A - Profármacos de moduladores del receptor de nmda - Google Patents

Profármacos de moduladores del receptor de nmda

Info

Publication number
ECSP22003599A
ECSP22003599A ECSENADI20223599A ECDI202203599A ECSP22003599A EC SP22003599 A ECSP22003599 A EC SP22003599A EC SENADI20223599 A ECSENADI20223599 A EC SENADI20223599A EC DI202203599 A ECDI202203599 A EC DI202203599A EC SP22003599 A ECSP22003599 A EC SP22003599A
Authority
EC
Ecuador
Prior art keywords
nmda receptor
prodrugs
receptor modulator
compounds
depression
Prior art date
Application number
ECSENADI20223599A
Other languages
English (en)
Inventor
John Kilburn
Laurent David
Mauro Marigo
Erhad Ascic
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of ECSP22003599A publication Critical patent/ECSP22003599A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se refiere a profármacos novedosos de moduladores del receptor de NMDA de fórmula I. Otros aspectos de la invención se refieren a composiciones farmacéuticas que comprenden dichos compuestos y a usos de los compuestos para tratar trastornos neurológicos o trastornos neuropsiquiátricos tales como la depresión.
ECSENADI20223599A 2019-07-03 2022-01-17 Profármacos de moduladores del receptor de nmda ECSP22003599A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201900822 2019-07-03

Publications (1)

Publication Number Publication Date
ECSP22003599A true ECSP22003599A (es) 2022-02-25

Family

ID=71614856

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20223599A ECSP22003599A (es) 2019-07-03 2022-01-17 Profármacos de moduladores del receptor de nmda

Country Status (20)

Country Link
US (2) US11358971B2 (es)
EP (1) EP3994140A1 (es)
JP (1) JP2022538180A (es)
KR (1) KR20220034052A (es)
CN (1) CN114008053A (es)
AR (1) AR119341A1 (es)
AU (1) AU2020299410A1 (es)
BR (1) BR112021003983A2 (es)
CA (1) CA3144303A1 (es)
CL (1) CL2021003534A1 (es)
CO (1) CO2021017154A2 (es)
CR (1) CR20210663A (es)
EC (1) ECSP22003599A (es)
IL (1) IL289576A (es)
JO (1) JOP20210332A1 (es)
MA (1) MA56450A (es)
MX (1) MX2021015752A (es)
PE (1) PE20220136A1 (es)
TW (1) TW202116780A (es)
WO (1) WO2021001420A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11466027B2 (en) 2019-07-03 2022-10-11 H. Lundbeck A/S Modulators of the NMDA receptor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026700A (en) 1989-05-16 1991-06-25 Merrell Dow Pharmaceuticals Certain quinolines and thienopyridines as excitatory amino acid antagonists
US5252581A (en) 1992-07-20 1993-10-12 Hoechst-Roussel Pharmaceuticals Inc. Substituted aminothienopyridines, pharmaceutical composition and use
US6071970A (en) 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
RU2201224C2 (ru) 1994-02-08 2003-03-27 Эн-Пи-Эс Фармасьютикалз, Инк. Соединения, активные в новом сайте на рецептор-регулируемых кальциевых каналах и используемые для лечения неврологических расстройств и заболеваний
EP0912494A1 (en) 1996-06-07 1999-05-06 Nps Pharmaceuticals, Inc. Coumpounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
WO1998056752A1 (en) 1997-06-11 1998-12-17 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
GB0401332D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
US9271967B2 (en) * 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
JP5852666B2 (ja) * 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
JP7071917B2 (ja) * 2015-12-09 2022-05-19 カデント セラピューティクス，インコーポレーテッド ヘテロ芳香族ｎｍｄａ受容体モジュレーターおよびその使用
JP7332472B2 (ja) * 2016-12-22 2023-08-23 ノバルティス アーゲー Ｎｍｄａ受容体モジュレーターおよびその使用
US11466027B2 (en) 2019-07-03 2022-10-11 H. Lundbeck A/S Modulators of the NMDA receptor

Also Published As

Publication number Publication date
PE20220136A1 (es) 2022-01-27
US11358971B2 (en) 2022-06-14
CA3144303A1 (en) 2021-01-07
BR112021003983A2 (pt) 2022-03-15
MA56450A (fr) 2022-05-11
CR20210663A (es) 2022-02-22
WO2021001420A1 (en) 2021-01-07
JOP20210332A1 (ar) 2023-01-30
EP3994140A1 (en) 2022-05-11
AR119341A1 (es) 2021-12-09
IL289576A (en) 2022-03-01
TW202116780A (zh) 2021-05-01
KR20220034052A (ko) 2022-03-17
CN114008053A (zh) 2022-02-01
US20220213117A1 (en) 2022-07-07
MX2021015752A (es) 2022-01-27
JP2022538180A (ja) 2022-08-31
CO2021017154A2 (es) 2022-01-17
US20210047342A1 (en) 2021-02-18
AU2020299410A1 (en) 2022-02-03
CL2021003534A1 (es) 2022-08-19

Similar Documents

Publication Publication Date Title
BR112021021703A2 (pt) Cicloalquilas substituídas como moduladores da via de estresse integrada
CU20210080A7 (es) Triazinas sustituidas como inhibidores de proteína tirosina fosfatasa
CL2020000422A1 (es) Composiciones de glp-1 y sus usos.
DOP2018000204A (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos
CO2017012545A2 (es) Sulfonas tricíclicas como moduladores del receptor huérfano relacionado con retinoide gamma (rorγ)
DOP2017000118A (es) 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1
DOP2017000117A (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
CO2018013240A2 (es) Oligonucleótidos antisentido para modular la expresión de htra1
CR20190392A (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
BR112018075201A2 (pt) moduladores do receptor beta-3 adrenérgico úteis para o tratamento ou prevenção de distúrbios relacionados com os mesmos
NI201900075A (es) Compuesto moduladores del receptor de hidrocarburos de arilo (ahr)
DOP2018000058A (es) Inhibidores de ezh2
UY36209A (es) Derivados de la pirazina como agonistas moduladores del receptor gpr40 y composiciones farmacéuticas que los contienen
CL2019003274A1 (es) Derivados de pirimidina como moduladores del receptor de pge2.
CL2018001210A1 (es) Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico.
BR112017008312A2 (pt) novos compostos de piridopirimidinona para modular a atividade catalítica de histona lisina demetilases (kdms)
ECSP20067907A (es) Moduladores alostéricos de espiropiperidina de receptores nicotínicos de acetilcolina
ECSP22003599A (es) Profármacos de moduladores del receptor de nmda
BR112017016378A2 (pt) composições da pró-droga de fumarato de monometila
ECSP22003596A (es) Moduladores del receptor de nmda
CO2019013317A2 (es) Oligonucleótidos antisentido para la modulación de la expresión de htra1
CO2021001174A2 (es) Inhibidores de ckd8/19
ECSP22007557A (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
CL2022002986A1 (es) Compuestos derivados de azetidina-3-ilmetanol como moduladores del receptor ccr6
DOP2022000026A (es) Derivados de alcohol como abridores del canal de potasio kv7